Mirtazapina Flas Viatris (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Viatris, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Flas Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used to treat depressive disorders by modulating noradrenergic and serotonergic pathways.

Major depressive disorder: reduces depressive symptoms and improves mood in adults. Depressive episodes in bipolar disorder (off‑label): may help alleviate depressive phases when other options are unsuitable. Depression with insomnia: can improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction - Severe hypersensitivity reactions (rash, angioedema) - Suicidal ideation or worsening depression - Seizures - Serotonin syndrome when combined with other serotonergic agents

Before prescribing mirtazapine, clinicians should consider several safety factors.

Liver function: assess hepatic status before initiating therapy. Suicidal thoughts: monitor for worsening depression or emergence of suicidal ideation, especially early in treatment. Cardiovascular disease: use caution in patients with known heart conditions due to potential orthostatic hypotension. Renal impairment: adjust dose in severe renal dysfunction. Discontinuation: avoid abrupt cessation; taper under medical supervision. Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase mirtazapine plasma levels. - CYP inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive drugs: possible additive blood‑pressure lowering effect.